The SATE pronucleotide approach applied to acyclovir. Part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo

Antiviral Research

Volumn 40, Issue 3, 1999, Pages 179-187

  Hantz, Olivier ^a   Périgaud, Christian ^b   Borel, Christelle ^a   Jamard, Catherine ^a   Zoulim, Fabien ^a   Trépo, Christian ^a   Imbach, Jean Louis ^b   Gosselin, Gilles ^b  

^a INSERM   (France)

^b Laboratoire de Chimie Bioorganique   (France)

Author keywords

Duck hepatitis B virus; Nucleotide; Prodrug

Indexed keywords

ACICLOVIR; ACICLOVIR DERIVATIVE; NUCLEOSIDE ANALOG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DUCK; HEPATITIS B VIRUS; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER CELL CULTURE; NEWBORN; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS REPLICATION;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; BLOTTING, SOUTHERN; CELLS, CULTURED; DNA, VIRAL; DRUG EVALUATION, PRECLINICAL; DUCKS; HEPADNAVIRIDAE INFECTIONS; HEPATITIS B VIRUS, DUCK; LIVER; NUCLEOTIDES; PHOSPHONIC ACIDS; PRODRUGS; VIRUS REPLICATION;

ANAS SP.; ANIMALIA; DNA VIRUSES; DUCK HEPATITIS B VIRUS; HEPATITIS B VIRUS;

EID: 0345059238     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00060-6     Document Type: Article

References (38)

1. Alexander P., Holý A. Prodrugs of analogs of nucleic acid components. Collect. Czech. Chem. Commun. 59:1994;2127-2165.
2. Benzaria S., Pélicano H., Johnson R., Maury G., Imbach J.-L., Aubertin A.-M., Obert G., Gosselin G. Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl] adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. J. Med. Chem. 39:1996;4958-4965.
3. Bishop N., Civitico G., Wang Y., Guo K., Birch C., Gust I., Locarnini S. Antiviral strategies in chronic hepatitis B virus infection. J. Med. Virol. 31:1990;82-89.
4. Dannaoui E., Trépo C., Zoulim F. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antivir. Chem. Chemother. 8:1997;38-46.
5. Fautz R., Hussein B., Hechenberger C. Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS). Mutat. Res. 253:1991;173-179.
6. Fourel I., Gripon P., Hantz O., Cova L., Lambert V., Jacquet C., Watanabe K., Fox J., Guillouzo C., Trépo C. Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: a useful system for antiviral testing. Hepatology. 10:1989;186-191.
7. Fourel I., Li J., Hantz O., Jacquet C., Fox J.J., Trépo C. Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis-B virus DNA level in serum and liver of chronically infected ducks. J. Med. Virol. 37:1992;122-126.
8. Fourel I., Saputelli J., Schaffer P., Mason W.S. The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J. Virol. 68:1994;1059-1065.
9. Girardet J.L., Périgaud C., Aubertin A.-M., Gosselin G., Kirn A., Imbach J.-L. Increase of the anti-HIV activity of d4T in human T-cell culture by the use of the SATE pronucleotide approach. Bioorg. Med. Chem. Lett. 5:1995;2981-2984.
10. Gosselin G., Girardet J.-L., Périgaud C., Benzaria S., Lefebvre I., Schlienger N., Pompon A., Imbach J.-L. New insights regarding the potential of the pronucleotide approach in antiviral chemotherapy. Acta Biochim. Pol. 43:1996;196-208.
11. Guarascio P., Defelici A.P., Migliorini D., Alexander G.J.M., Fagan E.A., Visco G. Treatment of chronic HBeAg-positive hepatitis with acyclovir. A controlled trial. J. Hepatol. 3:1986;S143-S147.
12. Gust I.D., Burrell C.J., Coulepis A.G., Robinson W.S., Zuckerman A.J. Taxonomic classification of human hepatitis B virus. Intervirology. 25:1986;14-29.
13. Hantz O., Allauden H.S., Ooka T., De Clercq E., Trépo C. Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-b-D-arabino-furanosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine. Antiviral Res. 4:1984;187-199.
14. Hantz O., Turin F., Trépo C. Therapy for hepatitis, with emphasis on the role of Interferons. Curr. Opin. Infect. Dis. 6:1993;778-783.
15. Heijtink R.A., Kruining J., Dewilde G.A., Balzarini J., De Clercq E., Schalm S.W. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. 38:1994;2180-2182.
16. Hoofnagle J.H., DiBisceglie A.M. Drug therapy: The treatment of chronic viral hepatitis. New Engl. J. Med. 336:1997;347-356.
17. Ilsley D.D., Lee S.H., Miller W.H., Kuchta R.D. Acyclic guanosine analogs inhibit DNA polymerase α, δ and ε with very different potencies and have unique mechanisms of action. Biochemistry. 34:1995;2504-2510.
18. Johansson N.G. Structure, antiviral activity, and chemistry of acyclic nucleoside analogues. De Clercq E. Advances in Antiviral Drug Design, Vol. 1. 1993;87-117 JAI Press, Greenwich.
19. Krise J.P., Stella V.J. Prodrugs of phosphates, phosphonates, and phosphinates. Adv. Drug Deliv. Rev. 19:1996;287-310.
20. Lambert V., Chassot S., Kay A., Trépo C., Cova L. In vivo neutralization of duck hepatitis B virus by antibodies specific to the N-terminal portion of pre-S protein. Virology. 185:1991;446-450.
21. Mason W.S., Cullen J., Saputelli J., Wu T.T., Liu C., London W.T., Lustbader E., Schaffer P., O'Connell A.P., Fourel I., Aldrich C.E., Jilbert A.R. Characterization of the antiviral effects of 2'-carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology. 19:1994;398-411.
22. O'Brien J.J., Campoli-Richards D.M. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 37:1989;233-309.
23. Périgaud C., Aubertin A.-M., Benzaria S., Pélicano H., Girardet J.-L., Maury G., Gosselin G., Kirn A., Imbach J.-L. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3'-azido-2',3'-dideoxythymidine. Biochem. Pharmacol. 48:1994;11-14.
24. Périgaud C., Girardet J.L., Gosselin G., Imbach J.-L. Comments on nucleotide delivery forms. De Clercq E. Advances in Antiviral Drug Design, Vol. 1. 1996a;144-172 JAI Press, Greenwich.
25. Périgaud C., Gosselin G., Imbach J.-L. A rational strategy for the design of anti hepatitis B virus nucleotide derivatives. Antiviral Ther. 1(Suppl.4):1996b;39-46.
26. Périgaud C., Girardet J.-L., Lefebvre I., Xie M.-Y., Aubertin A.-M., Kirn A., Gosselin G., Imbach J.-L., Sommadossi J.-P. Comparison of cytotoxicity of mononucleoside phosphotriester derivatives bearing biolabile phosphate protecting groups in normal human bone marrow progenitor cells. Antiviral Chem. Chemother. 7:1996c;338-345.
27. Périgaud C., Gosselin G., Imbach J.-L. Minireview: from the pronucleotide concept to the SATE phosphate protecting groups. Alexander J.C. Current Topics in Medicinal Chemistry, Vol. 2. 1997;15-29 Blackwell, Oxford.
28. Périgaud C., Gosselin G., Girardet J.-L., Korba B.E., Imbach J.-L The SATE pronucleotide approach applied to acyclovir. Part I. Synthesis and in vitro anti-HBV activity of bis(SATE)phosphotriester derivatives of acyclovir. Antiviral Res. 40:1999;167-178.
29. Pugh J.C., Summers J.W. Infection and uptake of duck hepatitis B virus by duck hepatocytes maintained in the presence of dimethyl sulfoxide. Virology. 172:1989;564-572.
30. Shaw T., Locarnini S.A. Hepatic purine and pyrimidine metabolism: Implications for antiviral chemotherapy of viral hepatitis. Liver. 15:1995;169-184.
31. Summers J., Smith P.M., Horwich A.L. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64:1990;2819-2824.
32. Turin F., Borel C., Benchaib M., Kay T., Jamard C., Guguen-Guillouzo C., Trépo C., Hantz O. n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes. J. Virol. 70:1996;2691-2696.
33. Valette G., Girardet J.-L., Pompon A., Périgaud C., Gosselin G., Aubertin A.-M., Kirn A., Imbach J.-L. The pronucleotide approach. III. Synthesis, stability studies and anti-HBV activity of bis(S-pivaloyl-2-thioethyl)phosphotriester derivative of acyclovir. Nucleosides Nucleotides. 16:1997;1331-1335.
34. Wagstaff A.J., Faulds D., Goa K.L. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 47:1994;153-205.
35. Weller I.V., Carreno V., Fowler M.J.F., Monjardino J., Makinen D., Thomas H.C., Sherlock S. Acyclovir inhibits hepatitis B virus in man. Lancet. 1:1982;273.
36. Yokota T., Konno K., Chonan E., Mochizuki S., Kojima K., Shigeta S., De Clercq E. Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrob. Agents Chemother. 34:1990;1326-1330.
37. Zoulim F., Dannaoui E., Borel C., Hantz O., Lin T.S., Liu S.H., Trépo C., Cheng Y.C. 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob. Agents Chemother. 40:1996;448-453.
38. Zuckerman A.J. Screening of antiviral drugs for hepadnavirus infection in Pekin duck: a review. J. Virol. Methods. 17:1987;119-126.